Header Logo

Connection

LAVANNYA PANDIT to Antibodies, Monoclonal

Back to Details
This is a "connection" page, showing publications LAVANNYA PANDIT has written about Antibodies, Monoclonal.
LAVANNYA PANDIT
Connection Strength
0.080
Antibodies, Monoclonal
  1. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis. 2022 05; 22(5):622-635.
    View in: PubMed
    Score: 0.080
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.